Slide 1: BioPorto A/S
BioPorto A/S CEO Peter M Eriksen presenting @ Biotech Showcase 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation
Slide 3: About BioPorto A/S
About BioPorto A/S BioPorto is an in vitro diagnostics company that uses our antibody • 400-800 Abs in significant disease states and assay expertise to transform • Steady source of revenue (275+ customers in 40+ countries) Antibody • Insight into high value diagnostic targets novel research tools i
Slide 4: BioPorto's Development Platform
BioPorto’s Development Platform Diabetes Obesity Cancer Antibody Infec- Library Allergy Auto- tious Disease immune Generic MBL Rapid ELISA Assay NGAL ELISAs Assay Device Development NGAL IVD Assay Actionable The NGAL Test™ Biomarkers 4
Slide 5: How The NGAL Test Can Improve Care
How The NGAL Test Can Improve Care Dr. Peter McCullough, Baylor “The incorporation of a structural biomarker indicating active kidney damage such as NGAL will greatly enhance our understanding of AKI/CKD and allow us to devise prevention and management strategies.” Dr. Jonathan Barash, Columbia “The
Slide 6: AKI: A Major Public Health Concern
AKI: A Major Public Health Concern 230% Increase 2 Million Deaths $10 Billion Increase AKI in 10 Years1 Each Year2 in US Hospital Costs3 More In-hospital Higher Higher AKI Mortality Costs Why? AKI is common, complex and lacking diagnostic tools to help quickly identify kidney injury and aid clinicia
Slide 7: Current Standard of Care is Slow and Non-specific
Current Standard of Care is Slow and Non-specific 0h 2h 48+h 72h Normal Increased Risk Damage Reduced Kidney Kidney Death Function Failure Serum Creatinine: 48-72 hours Standard of Care Faster & more specific diagnosis The NGAL Test within 2 hours Actionable Results 46-70h Sooner Shorter length of s
Slide 8: Case Study: NGAL Monitoring Improving Care
Case Study: NGAL Monitoring Improving Care Patient: 4 mo. old girl in the Cardiac ICU at Cincinnati Children's Hospital with hypoplastic left heart syndrome, respiratory failure & mechanical ventilation. Case Highlights Corresponding to Numbered Arrows 1) After 4 days in the CICU, nephrology was con
Slide 9: NGAL: An Early Warning System for Kidney Injury
NGAL: An Early Warning System for Kidney Injury A small protein expressed in neutrophils and certain epithelia, including the renal tubules Produced rapidly by the kidney in response to injury Fastest responding biomarker2 40% NGAL detected approximately NGAL levels increase 48-72 hours before s
Slide 10: The NGAL Test: Benefits Across the Healthcare Ecosystem
The NGAL Test: Benefits Across the Healthcare Ecosystem Patient Provider Faster identification of AKI risk Better triage decisions Earlier interventions to limit kidney damage Avoid unnecessary tests/therapies Faster feedback on interventions Fewer missed cases of AKI Avoid false negative diagnoses
Slide 11: Clinical Applications of NGAL
Clinical Applications of NGAL Applications in Adult Populations & Settings Pediatric Indication “The limitation in AKI detection may be limiting 1 in 3 children is doctors’ abilities to get 1 in 5 adults is affected with affected with AKI ahead of injury... AKI during a hospital episode during a hos
Slide 12: The NGAL Test: Indications & Opportunities
The NGAL Test: Indications & Opportunities Exclusion of AKI in the ED ~120 M Tests ~$2.4B (Label expansion) Monitoring of AKI ~65 M Tests ~$1.3B (Label expansion) Pediatric Patients ~5-10M Tests ~$100-200M Beyond 2020 (Retrospective trial initiated Q4 2018) Growth Areas • Cancer Risk Prediction in I
Slide 13: Driving Commercialization Through Key Partnerships
Driving Commercialization Through Key Partnerships Establish Clinical Value KOL relationships Commercialization Roles Clinical Studies Papers, Posters & Podium BioPorto Enable Rapid Hospital Uptake Key Account Focus Hospital relationships IDN & Value Based Care Expand in Strategic Established Networ
Slide 14: 2019 Milestones
2019 Milestones • Supplementary data to FDA to support initial FDA clearance in adults (1H 2019) • Approval of NGAL (plasma) in adults (2H 2019) • Submission of urinary NGAL test for pediatric population (1H 2019) Clinical and • Approval of NGAL in pediatrics (2019) Regulatory • Onboard US Commercia
Slide 15: Investment Highlights
Investment Highlights Platform Broad Target Market • Antibody → Assay → Actionable Biomarker • The NGAL Test Addresses $5 B AKI Market Repeatable Development Path • Significant Unmet Diagnostic Needs • Robust Academic & Research Relationships • Testing can speed diagnosis, saving costs and • $4M Rev
Slide 16: Thank you
Thank you Sf BioPoRTO: